Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Arena Pharmaceuticals
Pharma
Eisai ends lorcaserin development in Dravet syndrome
In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor agonist lorcaserin.
Fraiser Kansteiner
Nov 18, 2024 10:18am
Pfizer to press pause on large M&A deals, CEO says
Jun 11, 2024 10:50am
Top 10 biopharma M&A deals in 2021
Jan 18, 2022 3:00am
Eisai will pull Belviq off U.S. shelves on cancer concerns
Feb 14, 2020 9:32am
Novo preps big obesity push, undeterred by its rivals' fates
Nov 21, 2017 11:57am
Chasing a payday, new drugmakers favor solo launches: report
Apr 17, 2017 11:22am
